Koninklijke Philips (NYSE:PHG) Shares Sold by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC lowered its stake in shares of Koninklijke Philips (NYSE:PHG) by 4.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,934,019 shares of the technology company’s stock after selling 85,675 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Koninklijke Philips were worth $48,737,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Mondrian Investment Partners LTD boosted its holdings in Koninklijke Philips by 45.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 9,553,058 shares of the technology company’s stock worth $191,061,000 after buying an additional 2,971,008 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Koninklijke Philips by 361.7% in the first quarter. Jane Street Group LLC now owns 629,136 shares of the technology company’s stock valued at $12,583,000 after acquiring an additional 492,881 shares in the last quarter. Brandes Investment Partners LP boosted its stake in shares of Koninklijke Philips by 48.7% in the fourth quarter. Brandes Investment Partners LP now owns 1,285,935 shares of the technology company’s stock worth $30,001,000 after acquiring an additional 421,055 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Koninklijke Philips by 36.4% during the first quarter. Russell Investments Group Ltd. now owns 1,410,067 shares of the technology company’s stock worth $28,201,000 after purchasing an additional 376,244 shares in the last quarter. Finally, OLD Mission Capital LLC raised its stake in Koninklijke Philips by 434.9% in the 4th quarter. OLD Mission Capital LLC now owns 434,282 shares of the technology company’s stock valued at $10,132,000 after purchasing an additional 353,096 shares during the last quarter. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Stock Down 0.1 %

PHG stock opened at $30.74 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.74 and a debt-to-equity ratio of 0.60. The firm has a 50-day moving average of $28.44 and a two-hundred day moving average of $25.36. Koninklijke Philips has a 12 month low of $17.75 and a 12 month high of $30.91. The company has a market cap of $28.89 billion, a price-to-earnings ratio of -32.02, a PEG ratio of 1.05 and a beta of 0.73.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings results on Monday, July 29th. The technology company reported $0.32 EPS for the quarter. Koninklijke Philips had a positive return on equity of 10.15% and a negative net margin of 2.35%. The firm had revenue of $4.80 billion during the quarter. As a group, analysts forecast that Koninklijke Philips will post 1.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.